Planté-Bordeneuve and colleagues reported the effect of tafamidis in 43 TTR-FAP-treated patients with a variety of mutations (53% non-V30M TTR) at different stages of neuropathy followed long term. The gene discussed is FAP; the disease is neuropathy.